Literature DB >> 24706229

Dermatologic infections in cancer patients.

Mona Gandhi1, Joaquin C Brieva, Mario E Lacouture.   

Abstract

Dermatologic infections are among the most commonly experienced complications of cancer and anti-cancer therapy. Alterations in host immune function secondary to the underlying malignant process and/or its treatment have been linked to an increase in the risk of infections. The skin and its appendages (i.e., hair and nails) represent the first line of defense against infectious microorganism; its dysfunction as a physical barrier and an immunologic organ in cancer patients leads to an increased susceptibility to infectious organisms. Moreover, a cancer patient's vulnerable state facilitates dissemination of infections to other sites, secondarily involving the skin. This chapter delineates dermatologic infections that are unique to cancer patients as a result of their underlying malignancies and associated comorbidities as well as those resulting from antineoplastic therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706229     DOI: 10.1007/978-3-319-04220-6_10

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  4 in total

1.  Dermatologic infections in cancer patients treated with checkpoint inhibitors.

Authors:  Mytrang H Do; Dulce M Barrios; Gregory S Phillips; Michael A Postow; Allison Betof Warner; Jonathan E Rosenberg; Sarah J Noor; Alina Markova; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2021-03-17       Impact factor: 11.527

2.  Investigation of the Dermal Absorption and Irritation Potential of Sertaconazole Nitrate Anhydrous Gel.

Authors:  Mahima Manian; Kumpal Madrasi; Ayyappa Chaturvedula; Ajay K Banga
Journal:  Pharmaceutics       Date:  2016-07-07       Impact factor: 6.321

3.  Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

Authors:  J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover
Journal:  Invest New Drugs       Date:  2021-01-03       Impact factor: 3.651

4.  Local bacteria affect the efficacy of chemotherapeutic drugs.

Authors:  Panos Lehouritis; Joanne Cummins; Michael Stanton; Carola T Murphy; Florence O McCarthy; Gregor Reid; Camilla Urbaniak; William L Byrne; Mark Tangney
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.